Screener
Merck & Co. MRK Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Merck & Co. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Merck & Co.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:11 PM EDT
- Fiscal quarter
- Q3 FY2028
- Calendar quarter
- Q3 2028
- Accession
- 0000310158-26-000212
| ($ in millions) | June 30, 2026 / Amortized Cost | June 30, 2026 / Gross Unrealized / Gains | June 30, 2026 / Gross Unrealized / Losses | June 30, 2026 / Fair Value | December 31, 2025 / Amortized Cost | December 31, 2025 / Gross Unrealized / Gains | December 31, 2025 / Gross Unrealized / Losses | December 31, 2025 / Fair Value |
|---|---|---|---|---|---|---|---|---|
| Commercial paper | $292 | — | — | $292 | — | — | — | — |
| Foreign government bonds | — | — | — | — | 1 | — | — | 1 |
| U.S. government and agency securities | — | — | — | — | 100 | — | — | 100 |
| Total debt securities | $292 | — | — | $292 | $101 | — | — | $101 |
| Publicly traded equity securities (1) | 1,274 | 1,392 | ||||||
| Total debt and publicly traded equity securities | $1,566 | $1,493 |
Item 1. Financial Statements
FAQ
- What is Merck & Co.'s cash, cash equivalents, and marketable securities?
- Merck & Co. (MRK) reported cash, cash equivalents, and marketable securities of $292M in Q2 2026.
- How has Merck & Co.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Merck & Co.'s cash, cash equivalents, and marketable securities decreased by 58.7% year-over-year, from $707M to $292M.
- What is the long-term trend for Merck & Co.'s cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Merck & Co.'s cash, cash equivalents, and marketable securities has grown at a 2.6% compound annual growth rate (CAGR), from $89M to $101M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Merck & Co.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude